Sanderling Ventures - Investor Profile and Portfolio

Manufacturer of pharmaceutical products. The Company offers health solutions through its prescription medicines, vaccines, biological therapies, and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. The Company has operations in the Pharmaceutical, Animal Health, Alliances, and Healthcare Services segments. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. As of August 2014, Merck's research and development efforts have led to the approval of more new drugs than any other company. Research performed at Merck has led to U.S. FDA approval of 63 New Molecular Entities. In 2022, the company recorded annual revenues of $57.09B and a net profit of $13.03B.

Boston Scientific is a worldwide developer, manufacturer, and marketer of medical devices. Their products and technologies are used to diagnose or treat a wide range of medical conditions, including heart, digestive, pulmonary, vascular, urological, women's health, and chronic pain conditions. The devices include access devices, artificial sphincters, balloons, band ligators, catheters, defibrillators, guidewires, leads, needles, probes, and stents among others. It also develops surgical devices for minimally invasive surgery. Boston Scientific went public in May 1992. In 2022, the company recorded annual revenues of $12.68B and a net profit of $0.69B.

Developer of products to prevent and treat infectious and inflammatory diseases and cancer. The lead candidate Heplisav-B Hepatitis B Vaccine combines TLR9 agonist and hepatitis B surface antigen. also developing DV2-HBV-25 for myocardial infarction, DV2-HBV-26 for immune-mediated herpes zoster, and others.

Regeneron Pharmaceuticals is a developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others. It is developing antibody products include ARCALYST (rilonacept), an anti-inflammatory agent, EYLEA (aflibercept) Injection, also known as VEGF Trap-Eye, and Intravitreal Aflibercept injection. It has also developed PRALUENT (alirocumab) Injection that is a PCSK9 inhibitor. Its Phase 3 pipeline includes antibodies for the treatment of rheumatoid arthritis, topic dermatitis in adults, asthma, respiratory syncytial virus, chronic lower back pain, and others. Its Phase 2 pipeline drugs are for the treatment of Atopic dermatitis in children, nasal polyps, eosinophilic esophagitis, non-infectious uveitis, skeletal muscle disorders. In 2022, the company recorded annual revenues of $12.17B and a net profit of $4.33B.